TY - JOUR
T1 - Association between C-Reactive Protein Levels and Functional Disability in the General Older-Population
T2 - The Takashima Study
AU - Takashima, Naoyuki
AU - Nakamura, Yasuyuki
AU - Miyagawa, Naoko
AU - Kadota, Aya
AU - Saito, Yoshino
AU - Matsui, Kenji
AU - Miura, Katsuyuki
AU - Ueshima, Hirotsugu
AU - Kita, Yoshikuni
N1 - Funding Information:
We thank the members of this study for their contribution. This study was supported in part by grants from Research on Cardiovascular Disease (3A-1, 6A-5, and 7A-2) and Comprehensive Research on Cardiovascular and Lifestyle-related Diseases (H18-CVD-Ippan-029) of the Ministry of Health, Labour and Welfare; by a research grant from the Japan Arteriosclerosis Prevention Fund; by Omron Health Care Co. Ltd; by the Grants-in-Aid for Scientific Research (13670361, 17390186, 20390184, 17015018, 20790424, 22790544, 24390165, 16H06277, 17H04133, 19H03902, and 20K10484) of the Ministry of Education, Culture, Sports, Science, and Technology and the Japan Society for the Promotion of Science; and by Grant-in-Aid for Scientific Research on Priority Areas of Cancer (No. 17015018) and Innovative Areas (No. 221S0001).
Funding Information:
The Takashima Study was partially supported by Omron Health Care Co. Ltd. The study’s had no role in the study design, conduct of the study, data collection, data interpretation or preparation of the report. No other author has reported a potential conflict of interest relevant to this article. All authors have full access to all the data and take responsibility for their integrity and the accuracy of the analysis.
Publisher Copyright:
© 2023 Japan Atherosclerosis Society.
PY - 2023
Y1 - 2023
N2 - Aims: High-sensitivity C-reactive protein (hsCRP) associates with atherosclerotic diseases such as stroke. However, previous results on the association between hsCRP levels and functional disability were controversial. Methods: We analyzed 2,610 men and women who did not exhibit functional disability or death within the first 3 years of the baseline survey and those aged 65 years or older at the end of follow-up. The levels of hsCRP were assessed using latex agglutination assay at baseline survey from 2006 to 2014. Functional disability was followed up using the long-term care insurance (LTCI) program until November 1, 2019. Functional disability was defined as a new LTCI program certification. Cox proportional hazards model with competing risk analysis for death was used to evaluate the association between hsCRP levels and future functional disability. Results: During a 9-year follow-up period, we observed 328 cases of functional disability and 67 deaths without prior functional disability incidence. The multivariable-adjusted hazard ratio (HR, 95% confidence interval [CI]) of functional disability in log-transferred hsCRP levels was 1.43 (1.22–1.67) in men and 0.97 (0.81–1.15) in women. When hsCRP level was analyzed as a categorical variable, low hsCRP levels (<1.0 mg/l) as the reference, the multivariable-adjusted HR (95% CI) of functional disability in high hsCRP levels (≥ 3.0 mg/l) was 2.37 (1.56–3.62). Similar results were observed when stratified by sex, but it was not significant in women. Conclusions: This study demonstrates that low-grade systemic inflammation to assess hsCRP might predict the future incidence of functional disability, especially in men.
AB - Aims: High-sensitivity C-reactive protein (hsCRP) associates with atherosclerotic diseases such as stroke. However, previous results on the association between hsCRP levels and functional disability were controversial. Methods: We analyzed 2,610 men and women who did not exhibit functional disability or death within the first 3 years of the baseline survey and those aged 65 years or older at the end of follow-up. The levels of hsCRP were assessed using latex agglutination assay at baseline survey from 2006 to 2014. Functional disability was followed up using the long-term care insurance (LTCI) program until November 1, 2019. Functional disability was defined as a new LTCI program certification. Cox proportional hazards model with competing risk analysis for death was used to evaluate the association between hsCRP levels and future functional disability. Results: During a 9-year follow-up period, we observed 328 cases of functional disability and 67 deaths without prior functional disability incidence. The multivariable-adjusted hazard ratio (HR, 95% confidence interval [CI]) of functional disability in log-transferred hsCRP levels was 1.43 (1.22–1.67) in men and 0.97 (0.81–1.15) in women. When hsCRP level was analyzed as a categorical variable, low hsCRP levels (<1.0 mg/l) as the reference, the multivariable-adjusted HR (95% CI) of functional disability in high hsCRP levels (≥ 3.0 mg/l) was 2.37 (1.56–3.62). Similar results were observed when stratified by sex, but it was not significant in women. Conclusions: This study demonstrates that low-grade systemic inflammation to assess hsCRP might predict the future incidence of functional disability, especially in men.
KW - C-reactive protein
KW - Functional disability
KW - Systemic inflammatory
UR - http://www.scopus.com/inward/record.url?scp=85145492067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145492067&partnerID=8YFLogxK
U2 - 10.5551/jat.63323
DO - 10.5551/jat.63323
M3 - Article
C2 - 35264478
AN - SCOPUS:85145492067
SN - 1340-3478
VL - 30
SP - 56
EP - 65
JO - Journal of atherosclerosis and thrombosis
JF - Journal of atherosclerosis and thrombosis
IS - 1
ER -